The Kaali patent
The Kalli patent and the frequency therapy
The Kaali patent to blood electrification would probably still be slumbering in the archives of the Patent Office today if it weren't for a certain Dr. Robert Beck who was based on this patent, analyzed and refined the findings, and developed his Beck blood apperator based on this.
The story of the HIVirus began in 1981. In June, scientist Michael Gottlieb from UCLA (University of California Los Angeles) reported in a report for the Disease Control Convention about an unusual constellation of fungal infections and pneumonia in five apparently completely healthy, young, gay men from Los Angeles.
In 1985 the FDA the first HIV antibody test.
In 1989, the distribution of pentamidine for the prophylaxis of PCP (Pneumocystis Pneumonia) was approved by the FDA.
During this time there was worldwide research on the treatment of HIvirus and this is where the history of the Kaali blood electrification patent began.
Two researchers from the Albert Einstein College of Medicinie in New York experimented with HI virus in the petri dish. There were Dr. Steven Kaali and his then research colleague Dr. William Lyman, who was no longer named when the patent was filed.
The two scientists found that HI viruses can be deactivated with an extremely low current.
The results of their months of research were announced by the two scientists to an international audience on March 14, 1991 during the First Internation Symposium of Combinations Therapies (First International Congress in AIDS Research).
The experimental set-up as the basis for filing the Kaali patent was as follows:
HI viruses and white blood cells were found in a petri dish.
The contents of the petri dish were exposed to a weak electrical current.
In response to the current, the infection ability of the HI viruses decreased by up to 95%.
Since blood cells are much more robust than viruses from an electrophysiological point of view, currents of 50 to 100 microamperes are sufficient to weaken the pathogens, although the blood cells themselves are not damaged.
The HI viruses are not directly destroyed by the electrical current, but their outer protein envelope is impaired in such a way that you can no longer produce the enzyme "reverse transcriptase (RT)".
But it is precisely this enzyme “reverse transcriptase (RT)” that HI viruses need to be able to penetrate human body cells.
Because the RT enzyme is trained to break open the T body cells and the DNA this Zelle to be changed in such a way that the manipulated DNA of the body cell causes uncontrolled production of new HI viruses.
Due to the electrification of the blood, the HI viruses were no longer able to produce the RT enzyme that is important for them. Since they no longer had this enzyme after the electrical treatment, they could no longer penetrate the host cells. They had (as the result of the Kaali patent) lost their destructive ability to destroy the DNA of healthy body cells and to weaken and ultimately destroy the human immune system.
Kaali Patent No. 5.139.684
On February 23, 1993, the U.S. Patent Office issued Dr. Steven Kaali the patent No. 5.188.738.
You can find a link here: Google Patent Archive.
The Kaali patent was granted on the theory of blood electrification and describes two methods of introducing a certain alternating current into a virus-infected body fluid (e.g. blood), bacteriaTo kill viruses, fungi and parasites.
According to US patent law, the filing of a patent application must prove to the US Patent Office the effectiveness of the newly invented blood electrification in the experiment listed, in particular whether the neutralization of the HI viruses described has also succeeded.
To obtain this patent from the U.S. Patent Office, Dr. Kaali and his co-inventors have to prove that the discovery described also works in practice, otherwise the patent would never have been granted.
FDA and AMA on the Kaali patent
The, from Dr. Kaali's experimentally proven two-step application of HIV blood electrification, namely the "in-vitro treatment of HIV-infected blood by out-of-body blood washing or / and by surgical implantation and de-implantation of mini blood purifiers," came across because of the high cost and the unreasonable permanent monthly surgical procedures on high rejection by the FDA and the AMA.
Kaali subsequently developed a device with a small battery and two tiny electrodes that could be planted directly in an artery in the arm and leg.
However, monthly surgical interventions had to be carried out in order to reposition the electrodes again and again.
The cost of the American health care system would have been enormous.
$ 5.000 per patient per month would have been expected. Furthermore, it had to be taken into account that a decisive positive change in the patient could only be noticed after about 6 to 7 months.
The FDA (Federal Drug Administration), the highest US health authority, and the AMA (American Medical Administration), following an intensive review of the Kaali patent, produced the following, ethically and financially justified rejection:
• The "in vitro" method is ethically unacceptable
• The patient had to endure unreasonable long-term interventions
• The surgical effort is enormous
• This creates considerable risks for the patient
• The cost of one implantation each is over $ 5.000
• That would ruin the American health care system given the many HIV infections (1993)
On the basis of the US patent 5.139.684, research and documentation was carried out that the blood electrification works with viruses, bacteria etc. The necessary scientific evidence was attached to the patent.
Due to the technology at the time, the patent could not be applied to the patient in this form, which is why it was not used in the medical sense.
Dr. However, Robert Beck made this patent the basis of his further research and launched his Beck blood zapper some time later.
This device was small and handy, inexpensive and could be used on the patient without restrictions.
Don't miss any more articles! If you sign up for our monthly Newsletter register, you will receive all new publications of the last 30 days in compact form.